Amprenavir (Agenerase)是HIV蛋白酶抑制剂,Ki为0.6 nM。
Amprenavir is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Helsley RN, et al. Mol Pharmacol,?013, 83(6), 1190-1199.
分子式 C25H35N3O6S |
分子量 505.63 |
CAS号 161814-49-9 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 16 mg/mL |
Water <1 mg/mL |
Ethanol 101 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00002405 | HIV Infections | Drug: Amprenavir | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00002417 | HIV Infections | Drug: Amprenavir | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT02182765 | HIV Infections | Drug: Nevirapine|Drug: Amprenavir|Drug: Abacavir | Boehringer Ingelheim | Phase 1 | 1999-04-01 | 2014-07-11 |
NCT00002205 | HIV Infections | Drug: Abacavir sulfate|Drug: Amprenavir | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00038519 | HIV Infections | Drug: Amprenavir/ritonavir|Drug: Saquinavir/ritonavir | Abbott | Phase 2|Phase 3 | 2001-04-01 | 2006-07-27 |
NCT00001758 | HIV Infection | Drug: Abacavir|Drug: Amprenavir|Drug: Efavirenz | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) | Phase 2 | 1997-11-01 | 2008-03-03 |
NCT00196625 | HIV Infections | Drug: Amprenavir (drug)|Drug: ABT-378/r (drug)|Drug: Ritonavir (drug) | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 | 2000-11-01 | 2005-09-12 |
NCT00002245 | HIV Infections | Drug: Abacavir sulfate|Drug: Amprenavir|Drug: Lamivudine | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 3 | 1999-04-01 | 2005-06-23 |
NCT00038532 | HIV Infections | Drug: Amprenavir/ritonavir|Drug: Saquinavir/ritonavir|Drug: Efavirenz | Abbott | Phase 2 | 2001-04-01 | 2008-03-29 |
NCT00002193 | HIV Infections | Drug: Amprenavir | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 3 | 2005-06-23 | |
NCT00006591 | HIV Infections | Drug: Ritonavir|Drug: Amprenavir | Gathe, Joseph, M.D.|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00001095 | HIV Infections | Drug: Indinavir sulfate|Drug: Amprenavir|Drug: Nevirapine|Drug: Lamivudine|Drug: Stavudine|Drug: Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2012-02-16 | |
NCT00002419 | HIV Infections | Drug: Abacavir sulfate|Drug: Amprenavir|Drug: Efavirenz|Drug: Adefovir dipivoxil | Gilead Sciences|Glaxo Wellcome|Dupont Applied Biosciences|NIH AIDS Clinical Trials Information Service | Phase 2 | 2005-06-23 | |
NCT00002239 | HIV Infections | Drug: Enfuvirtide|Drug: Ritonavir|Drug: Abacavir sulfate|Drug: Amprenavir|Drug: Efavirenz | Hoffmann-La Roche|Trimeris | Phase 2 | 1999-05-01 | 2005-11-14 |
NCT00002202 | HIV Infections | Drug: Indinavir sulfate|Drug: Amprenavir | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 3 | 2005-06-23 | |
NCT00000912 | HIV Infections | Drug: Indinavir sulfate|Drug: Abacavir sulfate|Drug: Amprenavir|Drug: Nelfinavir mesylate|Drug: Efavirenz|Drug: Levocarnitine|Drug: Adefovir dipivoxil|Drug: Saquinavir | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2015-06-02 | |
NCT00005762 | HIV Infections | Drug: Indinavir sulfate|Drug: Ritonavir|Drug: Amprenavir|Drug: Nelfinavir mesylate|Drug: Efavirenz|Drug: Saquinavir | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-03-01 | 2013-07-19 | |
NCT00006617 | HIV Infections | Drug: Abacavir sulfate|Drug: Amprenavir|Drug: Lamivudine|Drug: Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome | 2015-05-14 | ||
NCT00001085 | HIV Infections | Drug: Amprenavir|Drug: Lamivudine|Drug: Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2012-02-14 | |
NCT00002195 | HIV Infections | Drug: Amprenavir|Drug: Lamivudine|Drug: Zidovudine | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 3 | 2005-06-23 | |
NCT00001766 | HIV Infection | Drug: Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) | Phase 1 | 1998-08-01 | 2008-03-03 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们